Literature DB >> 25152048

Is there a need for emerging drugs for the acute respiratory distress syndrome?

Marianne Fitzgerald1, Daniel F McAuley, Michael Matthay.   

Abstract

The acute respiratory distress syndrome (ARDS) is a common and devastating syndrome of acute respiratory failure for which little effective pharmacotherapy exists. The authors describe some interventions that show promise as potential therapies for this condition, with particular reference to clinically relevant human models of ARDS. Aspirin, mesenchymal stromal (stem) cells, keratinocyte growth factor, IFN-β and oncostatin M inhibition are discussed.

Entities:  

Keywords:  IFN-β; acute respiratory distress syndrome; aspirin; mesenchymal stromal cells; oncostatin M

Mesh：

Year:  2014        PMID： 25152048      PMCID： PMC4284055          DOI： 10.1517/14728214.2014.953052

Source DB:  PubMed          Journal:  Expert Opin Emerg Drugs        ISSN： 1472-8214            Impact factor:   4.191


  47 in total

Review 1.  The acute respiratory distress syndrome.

Authors:  L B Ware; M A Matthay
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

2.  Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury.

Authors:  Arnaud Goolaerts; Nadia Pellan-Randrianarison; Jérôme Larghero; Valérie Vanneaux; Yurdagül Uzunhan; Thomas Gille; Nicolas Dard; Carole Planès; Michael A Matthay; Christine Clerici
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-03-28       Impact factor: 5.464

3.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Authors:  Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-05-19       Impact factor: 30.700

4.  Acute respiratory distress in adults.

Authors:  D G Ashbaugh; D B Bigelow; T L Petty; B E Levine
Journal:  Lancet       Date:  1967-08-12       Impact factor: 79.321

5.  Palifermin for oral mucositis after intensive therapy for hematologic cancers.

Authors:  Ricardo Spielberger; Patrick Stiff; William Bensinger; Teresa Gentile; Daniel Weisdorf; Tarun Kewalramani; Thomas Shea; Saul Yanovich; Keith Hansen; Stephen Noga; John McCarty; C Frederick LeMaistre; Eric C Sung; Bruce R Blazar; Dieter Elhardt; Mon-Gy Chen; Christos Emmanouilides
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

6.  Association between use of lung-protective ventilation with lower tidal volumes and clinical outcomes among patients without acute respiratory distress syndrome: a meta-analysis.

Authors:  Ary Serpa Neto; Sérgio Oliveira Cardoso; José Antônio Manetta; Victor Galvão Moura Pereira; Daniel Crepaldi Espósito; Manoela de Oliveira Prado Pasqualucci; Maria Cecília Toledo Damasceno; Marcus J Schultz
Journal:  JAMA       Date:  2012-10-24       Impact factor: 56.272

7.  Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies.

Authors:  Arnaud W Thille; Andrés Esteban; Pilar Fernández-Segoviano; José-María Rodriguez; José-Antonio Aramburu; Patricio Vargas-Errázuriz; Ana Martín-Pellicer; José A Lorente; Fernando Frutos-Vivar
Journal:  Lancet Respir Med       Date:  2013-05-15       Impact factor: 30.700

Review 8.  Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

Authors:  V Wee Yong
Journal:  Neurology       Date:  2002-09-24       Impact factor: 9.910

9.  Rosuvastatin for sepsis-associated acute respiratory distress syndrome.

Authors:  Jonathon D Truwit; Gordon R Bernard; Jay Steingrub; Michael A Matthay; Kathleen D Liu; Timothy E Albertson; Roy G Brower; Carl Shanholtz; Peter Rock; Ivor S Douglas; Bennett P deBoisblanc; Catherine L Hough; R Duncan Hite; B Taylor Thompson
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

10.  Beta-Agonist Lung injury TrIal-2 (BALTI-2): a multicentre, randomised, double-blind, placebo-controlled trial and economic evaluation of intravenous infusion of salbutamol versus placebo in patients with acute respiratory distress syndrome.

Authors:  S Gates; G D Perkins; S E Lamb; C Kelly; D R Thickett; J D Young; D F McAuley; C Snaith; C McCabe; C T Hulme; F Gao Smith
Journal:  Health Technol Assess       Date:  2013-09       Impact factor: 4.014
View more
  4 in total

1.  Ablation of PDE4B protects from Pseudomonas aeruginosa-induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia.

Authors:  Lina Abou Saleh; Abigail Boyd; Ileana V Aragon; Anna Koloteva; Domenico Spadafora; Wadad Mneimneh; Robert A Barrington; Wito Richter
Journal:  FASEB J       Date:  2021-09       Impact factor: 5.834

2.  Neutrophils promote alveolar epithelial regeneration by enhancing type II pneumocyte proliferation in a model of acid-induced acute lung injury.

Authors:  Andrew J Paris; Yuhong Liu; Junjie Mei; Ning Dai; Lei Guo; Lynn A Spruce; Kristin M Hudock; Jacob S Brenner; William J Zacharias; Hankun D Mei; April R Slamowitz; Kartik Bhamidipati; Michael F Beers; Steven H Seeholzer; Edward E Morrisey; G Scott Worthen
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-09-30       Impact factor: 5.464

Review 3.  Extracorporeal membrane oxygenation (ECMO) and the acute respiratory distress syndrome (ARDS): a systematic review of pre-clinical models.

Authors:  Jonathan E Millar; Nicole Bartnikowski; Viktor von Bahr; Maximilian V Malfertheiner; Nchafatso G Obonyo; Mirko Belliato; Jacky Y Suen; Alain Combes; Daniel F McAuley; Roberto Lorusso; John F Fraser
Journal:  Intensive Care Med Exp       Date:  2019-03-25

4.  Dexamethasone fails to improve bleomycin-induced acute lung injury in mice.

Authors:  Mélissa Aubin Vega; Cécile Chupin; Mihai Pascariu; Anik Privé; André Dagenais; Yves Berthiaume; Emmanuelle Brochiero
Journal:  Physiol Rep       Date:  2019-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.